Jazz Pharmaceuticals plc (JAZZ) Stock
JAZZ has an Alpha Score of 51 out of 100 (weak), computed on Nov 3, 2026 from 3 of 4 sub-scores. 2 members of Congress disclosed 4 trades in JAZZ since 2021: 2 purchases and 2 sales, most recently Daniel Goldman (sale, Jul 12, 2023). Company insiders reported 0 open-market buys and 15 sales on SEC Form 4 in the 90 days to Nov 6, 2026. Its trailing P/E ratio is 14.5 and its net margin 20.4% (key statistics as of Oct 27, 2026).
What is JAZZ's Alpha Score?
How it works →Alpha Score of 51 reflects moderate overall profile with weak momentum, moderate value, moderate quality. Based on 3 of 4 signals – score is capped at 90 until remaining data ingests.
Computed from 3 of 4 sub-scores; a sub-score is left out when its inputs are missing, and the composite is capped accordingly.
Computed Nov 3, 2026
A rules-based research rating, not a recommendation to buy or sell.
Which members of Congress traded Jazz Pharmaceuticals plc (JAZZ)?
Most recent: Daniel Goldman (sale, Jul 12, 2023); records start Oct 19, 2021.
| Politician | Trade date | Type | Amount |
|---|---|---|---|
| Dan Goldman D-NY · House | 2023-07-12 | sale | $15k – $50k |
| Dan Goldman D-NY · House | 2023-03-06 | purchase | $15k – $50k |
| Dan Goldman D-NY · House | 2023-01-31 | sale | $1k – $15k |
| Tom Suozzi D-NY · House | 2021-10-19 | purchase | $1k – $15k |
From STOCK Act periodic transaction reports. House filings as of Nov 5, 2026.
See all JAZZ political trades →Are Jazz Pharmaceuticals plc insiders buying or selling?
SEC Form 4 filings| Date | Insider | Role | Type | Shares | Value |
|---|---|---|---|---|---|
| Nov 4, 26 | Carr Patricia | SVP, Chief Accounting Officer | SELL | 1.3K | $289K |
| Nov 4, 26 | Carr Patricia | SVP, Chief Accounting Officer | SELL | 163 | $38K |
| Nov 3, 26 | Gala Renee D | President & CEO | SELL | 1.0K | $225K |
| Nov 2, 26 | Cozadd Bruce C | Director | SELL | 6.0K | $1.3M |
| Oct 6, 26 | Gala Renee D | President & CEO | SELL | 2.0K | $473K |
| Oct 1, 26 | Cozadd Bruce C | Director | SELL | 6.0K | $1.4M |
| Sep 10, 26 | Patil Neena M | EVP & Chief Legal Officer | SELL | 1.2K | $289K |
| Sep 8, 26 | Gala Renee D | President & CEO | SELL | 2.0K | $486K |
| Sep 1, 26 | Cozadd Bruce C | Director | SELL | 6.0K | $1.5M |
| Aug 27, 26 | Iannone Robert | EVP, Global Head of R&D & CMO | SELL | 18.2K | $4.5M |
SEC Form 4 filings as of Nov 6, 2026
See cluster-buy signals across all tickers →What are JAZZ's key statistics?
Key statistics as of Oct 27, 2026
How does JAZZ's valuation compare with the Healthcare sector?
| Metric | JAZZ | Healthcare median | Companies in median |
|---|---|---|---|
| P/E ratio | 14.5 | 28.8 | 111 |
| Net margin | 20.45% | 3.66% | 168 |
| Return on equity | 21.37% | 3.80% | 191 |
Medians over the Healthcare stocks whose key statistics were refreshed in the last 35 days (newest Nov 8, 2026). P/E excludes loss-making companies.
JAZZ price chart
Powered by TradingViewWhat does Jazz Pharmaceuticals plc do?
Jazz Pharmaceuticals plc is a biopharmaceutical company dedicated to identifying, developing, and commercializing innovative medicines that address unmet medical needs in serious diseases. It maintains a diverse portfolio of marketed products targeting rare epilepsies such as with Epidiolex, sleep disorders including narcolepsy treatments like Xyrem and Xywav, and various cancers through therapies like Zepzelca, Vyxeos, and Ziihera for specific indications including metastatic small cell lung cancer and HER2-positive biliary tract cancer. The company also offers treatments for rare diseases, hematology, and neuroscience conditions, supported by a robust pipeline of therapeutics. Jazz Pharmaceuticals plc operates globally with a patient-focused, science-driven approach, advancing research in oncology, neurology, and rare disease areas to transform patient lives. Founded in 2003 and headquartered in Dublin, Ireland, it plays a significant role in the biopharmaceutical market by providing specialized therapies where treatment options are limited.